Atossa Genetics Inc. (ATOS) Reaches $2.84 After 8.00% Down Move; Shorts at Alteryx Class A (AYX) Raised By 4.34%

June 5, 2018 - By Marie Mckinney

Atossa Genetics Inc. (NASDAQ:ATOS) Logo

Alteryx Inc Class A (NYSE:AYX) had an increase of 4.34% in short interest. AYX’s SI was 3.27 million shares in June as released by FINRA. Its up 4.34% from 3.14 million shares previously. With 465,600 avg volume, 7 days are for Alteryx Inc Class A (NYSE:AYX)’s short sellers to cover AYX’s short positions. The SI to Alteryx Inc Class A’s float is 17.21%. The stock increased 1.93% or $0.68 during the last trading session, reaching $35.92. About 341,165 shares traded. Alteryx, Inc. (NYSE:AYX) has risen 69.22% since June 5, 2017 and is uptrending. It has outperformed by 56.65% the S&P500. Some Historical AYX News: ; 23/04/2018 – WHALE ROCK CAPITAL MANAGEMENT LLC REPORTS 6.36 PCT PASSIVE STAKE IN ALTERYX INC AS OF APRIL 13, 2018 – SEC FILING; 09/05/2018 – Alteryx Sees 2Q Rev $43M-$44M; 09/05/2018 – Alteryx Sees 2018 Rev $183M-$186M; 01/05/2018 – Alteryx Invites Customers to an Unconventional Convention to Alter Everything at Inspire 2018; 09/05/2018 – Alteryx Sees 2018 Adj Loss/Shr 22c-Adj Loss/Shr 27c; 09/05/2018 – Alteryx Sees 2Q Adj Loss/Shr 10c-Adj Loss/Shr 11c; 03/05/2018 – Alteryx Expands to Alter Analytics in France; 24/05/2018 – Alteryx Presenting at Cowen Conference May 30; 06/03/2018 Alteryx Alters Data Science with New Release; 20/04/2018 – DJ Alteryx Inc Class A, Inst Holders, 1Q 2018 (AYX)

The stock of Atossa Genetics Inc. (NASDAQ:ATOS) is a huge mover today! The stock decreased 3.40% or $0.1 during the last trading session, reaching $2.84. About 135,541 shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 41.40% since June 5, 2017 and is downtrending. It has underperformed by 53.97% the S&P500. Some Historical ATOS News: ; 23/04/2018 – Atossa Genetics lnforms Stockholders of Key Dates and Terms Related to Announced Rights Offering; 08/03/2018 Atossa Genetics Announces 2017 Financial Results and Provides Company Update; 24/04/2018 – ATOSSA GENETICS – INDEPENDENT SAFETY COMMITTEE REVIEWED BLINDED DATA FROM FIRST GROUP IN STUDY, CONCLUDED STUDY MAY ADVANCE TO NEXT DOSING LEVEL; 24/04/2018 – Atossa Genetics Receives Positive Interim Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation; 27/04/2018 – INTRACOASTAL CAPITAL LLC REPORTS 5.9 PCT PASSIVE STAKE IN ATOSSA GENETICS INC, AS OF APRIL 23, 2018 – SEC FILING; 24/04/2018 – Atossa Genetics Receives Positive Interim Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men; 23/04/2018 – Atossa Genetics Informs Stockholders of Key Dates and Terms Related to Announced Rights OfferingThe move comes after 8 months negative chart setup for the $7.53M company. It was reported on Jun, 5 by Barchart.com. We have $2.61 PT which if reached, will make NASDAQ:ATOS worth $602,560 less.

Alteryx, Inc. provides self-service data analytics software platform that enables organizations to enhance business outcomes and the productivity of their business analysts. The company has market cap of $2.18 billion. It offers Alteryx Designer for data preparation, blending, and analytics that could be deployable in the cloud and on premise; Alteryx Server, a secure and scalable product for sharing and running analytic applications in a Web environment; and Alteryx Analytics Gallery, a cloud collaboration offering that allows users to share workflows in a centralized repository. It currently has negative earnings. The firm serves clients in business and financial services, consumer goods, healthcare, retail, technology, and travel and hospitality industries in approximately 50 countries.

More important recent Alteryx, Inc. (NYSE:AYX) news were published by: Seekingalpha.com which released: “Alteryx: Overvalued Or ‘Under-Understood?'” on May 23, 2018, also Seekingalpha.com published article titled: “Alteryx Offers A Good Entry Point Here”, Seekingalpha.com published: “Alteryx Reports Revenue Deceleration In Q1: Valuation Is Rich” on May 14, 2018. More interesting news about Alteryx, Inc. (NYSE:AYX) was released by: Seekingalpha.com and their article: “Alteryx: The Pullback Will Be Short-Lived” with publication date: May 10, 2018.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $7.53 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

More important recent Atossa Genetics Inc. (NASDAQ:ATOS) news were published by: Nasdaq.com which released: “Atossa Genetics Announces First Quarter 2018 Financial Results And Provides Company Update” on May 14, 2018, also Seekingalpha.com published article titled: “Atossa Genetics’ (ATOS) Corporate Conference Call Transcript”, Nasdaq.com published: “Atossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical …” on May 15, 2018. More interesting news about Atossa Genetics Inc. (NASDAQ:ATOS) was released by: Nasdaq.com and their article: “Atossa Genetics To Host Corporate Conference Call Wednesday, May 16, 2018 at 4:30pm EDT” with publication date: May 14, 2018.

Alteryx, Inc. (NYSE:AYX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts